Parkinson’s disease, especially in early stage, may no longer trouble people in the future thanks to the new research of an inexpensive but rarely used drug - Selegiline - one from a group of drugs called monoamine oxidase type B inhibitors (MAOBIs). Researchers looked at 17 trials involving which are used to slow the progression of Parkinson’s.
